Clinical Trial Search

Primary: Percent Change From Baseline for Apolipoprotein B (ApoB) at Day 180 — -11.6; -14.1; -24.3; -19.0 Percent change — p=0.691

Primary: Changes Serum Triglyceride Levels — 223.1; 241.2; 227.0; 267.2 mg/dl — p=0.0001

Primary: Percentage Change From Baseline in the LDL-C/HDL-C Ratio — -50.9; -53.0; -37.6; -42.4 Percentage Change — p=<0.001

Primary: Triglycerides After 90 Days — 2.3; 1.1; 1.3 mmol/L

Primary: Percentage Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) — -44.6; -46.9; -48.9; -50.4 Percentage Change

Primary: Percent Changes From Baseline to End-of-treatment in Non-HDL Cholesterol, HDL Cholesterol, and Triglycerides by LCP-AtorFen Versus Atorvastatin Monotherapy — -44.8…

Primary: Reduction of LDL Cholesterol Levels — -39.45; -29.13 percent change of LDL — p=0.0013

Primary: Percent Change From Baseline at Week 24 in Fasting TG — -1.7; -51.5; -57.7; -64.1 percentage change — p=<0.0001

Primary: Percent Change From Baseline in Low Density Lipoprotein Cholesterol at Week 12 — -10.0; -5.5 Percent — p=0.006

Primary: Percentage of Triglyceride (TG) Change — -38.12 percentage of TG change

Primary: Total Cholesterol Before and After Simvastatin/Ezetimibe Administration — 255; 253; 180; 215 mg/dl — p=<0.05

Primary: Total Cholesterol (TC) Levels at First Acute Coronary Event — 163.5 mg/dL

Primary: Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12 — 4.94; 0.99; -65.35; -69.05 percent change — p=<0.0001

Primary: Percent Change From Baseline in Fasting TG at Week 24 — 7.55; -43.67; -49.01; -55.57 percentage change — p=<.0001

Primary: Percent Change From Baseline in Non-HDL-C at Week 24: Overall Intent-to-treat (ITT) Analysis — -37.3; -4.7 Percent change — p=<0.0001

Primary: Percentage of Participants Achieving Target Lipid Values — 46.8 Percentage of participants

Primary: Change From Baseline in Direct LDL-C at Week 8 — -2.0; -1.5; -4.2; 0.2 Percent change — p=0.06

Primary: Percent Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 6 — -36.5; -49.6; -39.4; -53.9 Percent Change — p=<0.001

Primary: Basal HDL-cholesterol Level — 39.5 mg/dL

Primary: Percent Change From Baseline to 12 Weeks Endpoint in High Density Lipoprotein Cholesterol (HDL-C) With LY2484595 in Combination With Atorvastatin and Atorvastatin…

Primary: Mean Percent Change in Low Density Lipoprotein Cholesterol(LDL-C) From Baseline to Week 12 — -34.8; -22.7 percent

Primary: Change in Non-HDL Cholesterol, HDL Cholesterol, TG Levels From Baseline to End of Treatment — -48.2; -43.6; -42.0; 2.6 percent change

Primary: Mean ApoB Concentration Before and After Evolocumab — 75.9; 35.3 mg/dL — p=<0.001

Primary: Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) (Phase I) — -24.8; -10.1; -13.8 Percentage Change — p=<0.001

Primary: Percentage of Change of TG (Triglyceride) — -30.6; 10.7; -27.3; -2.9 percentage of change

Primary: Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 — -0.8; -50.8 percent change — p=<0.001

Primary: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Endpoint, After 6 Weeks of Treatment — -32.2; -20.8 percentage change — p=0.005

Primary: Percent Change From Baseline Low Density Lipoprotein Cholesterol (LDL-C) — -40.78; -43.25 percent change

Primary: Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) (mg/dL) — -0.3; -1.5 Percent Change — p=0.926

Primary: Percentage of Subjects Reporting Adverse Events During Combination Therapy, Either in the Preceding Double-blind Studies or in This Open-label Study — 83; 86; 85…